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Abstract
Objective To evaluate whether a new computerised cognitive
behavioural therapy intervention (SPARX, Smart, Positive, Active,
Realistic, X-factor thoughts) could reduce depressive symptoms in help
seeking adolescents as much or more than treatment as usual.
Design Multicentre randomised controlled non-inferiority trial.
Setting 24 primary healthcare sites in New Zealand (youth clinics,
general practices, and school based counselling services).
Participants 187 adolescents aged 12-19, seeking help for depressive
symptoms, with no major risk of self harm and deemed in need of
treatment by their primary healthcare clinicians: 94 were allocated to
SPARX and 93 to treatment as usual.
Interventions Computerised cognitive behavioural therapy (SPARX)
comprising seven modules delivered over a period of between four and
seven weeks, versus treatment as usual comprising primarily face to
face counselling delivered by trained counsellors and clinical
psychologists.
Outcomes The primary outcome was the change in score on the
children’s depression rating scale-revised. Secondary outcomes included
response and remission on the children’s depression rating scale-revised,
change scores on the Reynolds adolescent depression scale-second
edition, the mood and feelings questionnaire, the Kazdin hopelessness
scale for children, the Spence children’s anxiety scale, the paediatric
quality of life enjoyment and satisfaction questionnaire, and overall
satisfaction with treatment ratings.
Results 94 participants were allocated to SPARX (mean age 15.6 years,
62.8% female) and 93 to treatment as usual (mean age 15.6 years,
68.8% female). 170 adolescents (91%, SPARX n=85, treatment as usual
n=85) were assessed after intervention and 168 (90%, SPARX n=83,
treatment as usual n=85) were assessed at the three month follow-up
point. Per protocol analyses (n=143) showed that SPARXwas not inferior
to treatment as usual. Post-intervention, there was a mean reduction of
10.32 in SPARX and 7.59 in treatment as usual in raw scores on the
children’s depression rating scale-revised (between group difference
2.73, 95% confidence interval −0.31 to 5.77; P=0.079). Remission rates
were significantly higher in the SPARX arm (n=31, 43.7%) than in the
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treatment as usual arm (n=19, 26.4%) (difference 17.3%, 95% confidence
interval 1.6% to 31.8%; P=0.030) and response rates did not differ
significantly between the SPARX arm (66.2%, n=47) and treatment as
usual arm (58.3%, n=42) (difference 7.9%, −7.9% to 24%; P=0.332). All
secondary measures supported non-inferiority. Intention to treat analyses
confirmed these findings. Improvements were maintained at follow-up.
The frequency of adverse events classified as “possibly” or “probably”
related to the intervention did not differ between groups (SPARX n=11;
treatment as usual n=11).
Conclusions SPARX is a potential alternative to usual care for
adolescents presenting with depressive symptoms in primary care
settings and could be used to address some of the unmet demand for
treatment.
Trial registration Australian New Zealand Clinical Trials
ACTRN12609000249257.
Introduction
Up to a quarter of young people will have experienced a
depressive disorder by the age of 19,1 which is a major cause
of disability.2 Effective therapies exist,3 with cognitive
behavioural therapy recommended as the preferred treatment
for mild to moderate depressive disorder.4However, fewer than
a fifth of young people with depressive disorder receive
treatment,5 6 partly because of shortages in the workforce7 and
partly because young people may be reluctant to seek traditional
help.8Computerised therapy offers a potential way forward and
may appeal to today’s “digital natives.”9 The cost of
computerised therapy is likely to be substantially lower than
traditional therapy and can increase access to treatment.10
Computerised cognitive behavioural therapy is effective for
depressed adults,11 although adherence to treatment can be
problematic.12 Recent reviews identified only eight studies on
four computerised interventions for depression in children and
adolescents.13 14 None was a randomised controlled trial of the
effectiveness of the intervention as a treatment for depression,
but both reviews concluded that this approach is promising.We
have carried out two small studies of computerised interventions
for depressive symptoms; one showed a significant effect
compared with placebo15 and the other was significantly more
effective than a waitlist control.16 A small open trial carried out
by another group showed encouraging results.17The other papers
identified were on depression prevention studies.
We designed a computerised cognitive behavioural therapy
intervention, SPARX (Smart, Positive, Active, Realistic,
X-factor thoughts), for adolescents seeking help for depression
and tested its effectiveness compared with treatment as usual.
We specifically aimed to design an intervention that would have
wide appeal to young people in New Zealand and elsewhere
and that would be enjoyable, thus resulting in good adherence
rates. If computerised cognitive behavioural therapy can reduce
symptoms and is at least as effective as treatment as usual it
would be worth disseminating, because of the associated lower
cost and the potential for reaching young people who currently
do not access help.
Methods
Our primary hypothesis was that SPARX would reduce
depressive symptoms as much or more than treatment as usual
as measured on the children’s depression rating scale-revised18
immediately after treatment compared with baseline. Our
secondary hypotheses were that SPARX would lead to
improvements as much or more than treatment as usual on self
rated measures of depression, anxiety and hopelessness, and
quality of life and on a clinician measure of overall
improvement; and the change seen at the end of treatment would
be maintained at follow-up (three months after completing the
intervention).
Trial design
We carried out a randomised controlled non-inferiority trial to
compare SPARX with treatment as usual. Outcome data were
collected at baseline, post-intervention (about two months after
the start of the intervention), and at follow-up three months later
(five months after the start of the intervention). Safety data were
collected at all time points, with an extra, brief check one month
after the start of intervention. Satisfaction with the intervention
was rated post-intervention and at the three month follow-up.
The only change to study methods after the trial started was a
change in sample size.
Participants
Young people seeking help for symptoms of depression, who
met the inclusion criteria, were recruited sequentially through
youth clinics (clinics specialising in providing primary
healthcare to adolescents and young adults), general practices,
and school based counselling services (in New Zealand, school
guidance counsellors are trained to provide counselling for
mental health problems and are often the first point of contact
for adolescents with difficulties) in seven provincial and urban
locations in New Zealand. We have labelled both healthcare
professionals and school guidance counsellors as “clinicians.”
We asked clinicians to use the score of 10-19 on the patient
health questionnaire-9 (the depression scale of the patient health
questionnaire),19 as a guide to ensure that young people had
clinically significant depression. However, we were inclusive
and, if young people reported that the depression was troubling
enough to need intervention and clinicians agreed with this
assessment, we accepted them. Participants were enrolled in the
trial according to the inclusion and exclusion criteria in box 1.
Interventions
SPARX is an interactive fantasy game designed to deliver
cognitive behavioural therapy for the treatment of clinically
significant depression. It utilises both first person instruction
and a three dimensional interactive game in which the young
person chooses an avatar and undertakes a series of challenges
to restore the balance in a fantasy world dominated by GNATs
(Gloomy Negative Automatic Thoughts). The program is
delivered on CD-ROM and has been designed to run on PCs
with reasonably low specifications (3 GHz or faster Intel
Pentium or equivalent processor, 512MRAM and 500MB hard
disc space). The game consists of seven modules (levels),
completed sequentially. Box 2 describes the content covered in
each module. At the beginning and end of each module, the user
interacts in the first person with a “guide,” who puts the game
into context, provides education, gauges mood, and sets and
monitors real-life challenges, equivalent to homework. Young
people who are not improving are prompted to seek help from
their referring clinicians. SPARX is supplemented by a paper
notebook with summaries of each module and spaces to add
comments about the challenges completed (a trailer of SPARX
is available at www.sparx.org.nz).
The control group was allocated to treatment as usual. At youth
clinics and school based counselling services, treatment as usual
was anticipated to be face to face therapy provided by trained
counsellors or psychologists. At general practices, treatment as
usual was likely to comprise assessment and treatment by
general practitioners with psychological treatment where
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Inclusion criteria
Presented for treatment with symptoms indicative of mild to moderate depressive disorder
Aged 12 to 19 years on the date of consent
Provided written consent or, if under age 16, written parental consent
Attended a clinical service or school based counselling service that was a study site
Achieved a minimum of one year of schooling in English
Had access to a computer to use SPARX
Exclusion criteria
A clinician assessed that the depression was too severe to make a self help resource a viable option
A clinician assessed the adolescent to be at high risk of self harm or suicide
Scored 7 on item 12 (morbid ideation) or 5 or higher on item 13 (suicidal ideation) on the children’s depression rating scale-revised
Raw score was less than 30 on children’s depression rating scale-revised
Intellectual disability or physical limitations precluded the use of the computer program
Had another major mental health disorder where the primary focus was not depression
Had had (in past three months) or was having treatment with cognitive behavioural therapy, interpersonal therapy, or antidepressants
Description of content and core skills covered in each module (level) of SPARX
Level 1—cave province: finding hope
Psychoeducation about depression and an introduction to the cognitive behavioural therapy model
Introducing GNATs (Gloomy Negative Automatic Thoughts)
Introducing “hope” (people recover from depression)
Relaxation: controlled breathing
Level 2—ice province: being active
Activity scheduling and behavioural activation
Relaxation: progressive muscle relaxation
Basic communication and interpersonal skills
Level 3—volcano province: dealing with emotions
Dealing with strong emotions: anger and hurt feelings
Interpersonal skills: assertiveness, listening, and negotiation
Level 4—mountain province: overcoming problems
Problem solving using STEPS: Say the problem, Think of solutions, Examine the pros and cons, Pick one and try it, See what happens
Cognitive restructuring-identifying SPARX: Smart, Positive, Active, Realistic, X-factor thoughts
Level 5—swamp province: recognising unhelpful thoughts
Cognitive restructuring—recognising different types of GNATs
Level 6—bridgeland province: challenging unhelpful thoughts
Cognitive restructuring—learning to challenge or “swap” negative thoughts for helpful ones
Interpersonal skills continued: negotiation skills
Level 7—canyon province: bringing it altogether
Recap of all skills
Mindfulness: tolerating distress
Relapse prevention: knowing when to ask for help
indicated and available. We collected data on the number and
duration of sessions and type of therapy.
Outcome measures
Primary outcome measure
The children’s depression rating scale-revised18 is an observer
rated scale developed specifically for children but often used
for adolescents.20 It has sound psychometric properties,21 is
widely used in clinical research,21 and has been used to assess
change in severity of depression in studies of treatment.20 22 The
scale can be used as a screening and diagnostic tool and as a
measure of severity of depression. It covers 17 symptom areas,
which are rated on a seven point or five point scale, with the
higher rating suggesting more severe difficulties.18 In our study
population the Cronbach’s α coefficient was 0.84. We trained
and supervised research assistants, who were blinded to the
intervention, to carry out the ratings.
Secondary outcome measures
For our secondary outcome measures we chose the following
self rated scales on the basis of psychometric properties and
ease of use:
• The Reynolds adolescent depression scale-second edition23
is a 30 item self report measure developed to evaluate the
severity of depressive symptoms in adolescents.20 Its
reliability, validity, and normative data are well
documented.20Mean raw scores in the range 76-81 fall into
the mild clinical depression range.23 The scale has been
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2598 doi: 10.1136/bmj.e2598 (Published 19 April 2012) Page 3 of 16
RESEARCH
validated for use in NewZealand adolescents.24 In our study
population the Cronbach’s α coefficient was 0.91.
• The mood and feelings questionnaire25 is a brief (33 items)
self administered measure designed to detect clinical
depression in children and adolescents. In our study
population the Cronbach’s α coefficient was 0.91.
• The paediatric quality of life enjoyment and satisfaction
questionnaire26 is a quality of life self report measure
designed specifically for use in children and adolescents.
It covers 15 areas and ratings are made on a five point scale
from “very poor” to “very good.” In our study population
the Cronbach’s α coefficient was 0.89.
• The Spence children’s anxiety scale27 is a well validated
46 item self report scale measuring child anxiety. In
addition to a total score, it has six subscales, which measure
specific types of anxiety. In our study population the
Cronbach’s α coefficient for the total score was 0.86.
• The Kazdin hopelessness scale for children28 is a 17 item
modification of the Beck hopelessness scale.28 It is self
administered and has been widely used in studies of
suicidality in youth. In our study population the Cronbach’s
α coefficient was 0.84.
The clinicians also rated change on the improvement domain
of the clinical global impression scale.29 It is a widely used single
item scale requiring the assessor to rate howmuch the participant
has changed relative to a baseline state (on a seven point scale
from “very much improved” to “very much worse”).
Participants completed a short questionnaire developed for the
purpose of this study to assess satisfaction with and enjoyment
of the allocated intervention.
Sample size
Using data from a pilot study by our group we calculated that
about 300 participants per arm (600 total) would be required to
power this non-inferiority study and allow some latitude for
exploration of subgroup (sex, age, ethnicity, setting, and baseline
depression) effects on efficacy. The pilot study included 34
participants with similar eligibility criteria, identical primary
outcomemeasures, and the same timing of the primary outcome
as participants in this trial. The standard deviation of the change
on the children’s depression rating scale-revised was 28. Using
two tailed 95% confidence intervals, non-inferiority (not worse
than 5.5 units inferior change on the children’s depression rating
scale-revised) would be identified with 80% power if about 600
participants were recruited. The children’s depression rating
scale-revised contains several categories—for example,
“depressive disorder might be confirmed in a comprehensive
diagnostic evaluation” and “depressive disorder is likely to be
confirmed.” The range of raw scores between these categories
is 12-14.We argued that a difference of less than half a category
was not likely to be clinically significant. When the recruitment
rate was well below our anticipated targets, we extended the
recruitment period and decided that adequately powered
subgroup analyses would not be feasible. We recalculated the
sample size for overall efficacy based on our accumulated data.
This revised power calculation was undertaken as an interim
summary of the overall variance of the change, not to test any
of the study hypotheses, and therefore did not unblind us to
treatment allocation. We estimated the variation in change on
the children’s depression rating scale-revised, based on the 55
participants (26 treatment as usual, 29 SPARX) who had
baseline and post-intervention scores on that scale. The standard
deviation of the change in scores based on this interim summary
was 10.2, considerably less than the original estimate. Using
this estimate and the same variables above, the power calculation
indicated a revised total sample size of 190 participants. This
calculation allows for about 30% attrition from the intention to
treat population; this 30% includes those potentially lost to
follow-up or not adhering to the treatment protocol.
Randomisation and sequence generation
We randomly allocated participants to SPARX or treatment as
usual in a 1:1 ratio, using a computer generated randomisation
sequence prepared before any participants were randomised.
Allocation was stratified by study site and arranged in permuted
blocks of 4.
Potential participants were informed about the study by their
clinicians. A research assistant not involved in the participants’
clinical care confirmed eligibility. To ensure allocation
concealment, once eligibility had been confirmed, the participant
was given an opaque sealed envelope containing the randomised
allocation. The young person took this to a local investigator
who opened the envelope, informed the young person of the
allocation, and organised access to SPARX or treatment as
usual. The assessment package and randomisation envelopes
were stored off-site and were available only to the research
assistants.
Blinding
It was not possible to blind the participants or treatment
providers. However, trained research assistants, blinded to
treatment allocation, carried out all assessments and
administered the rating scales. Those analysing data were
unaware of the treatment allocation. Research assistants, staff
at treatment centres, and the participants were briefed to not
discuss which treatment participants were receiving.
Statistical analysis
The primary analyses testing non-inferiority were undertaken
on the per protocol population, with sensitivity analyses on the
intention to treat population.30Both sets of results are presented.
The per protocol population included those who received
SPARX as per protocol (defined as completing at least four out
of seven modules) and met all other requirements of the
protocol. We used a general linear mixed model analysis to
compare changes in all metric outcomes between treatments,
with the site/stratum as a random between participants factor,
and the baseline level as a covariate. The results of these
analyses are summarised as the mean changes (95% confidence
intervals) for each group and the mean difference in these
changes (95% confidence intervals) between groups. We used
χ2 tests to compare remission and response rates between
randomised groups. Response was defined as a 30% decrease
in symptoms on the children’s depression rating scale-revised18
after correcting for the non-zero minimum on the scale (by
subtracting the scale minimum of 17 from each score), and
remission was defined as a raw score on children’s depression
rating scale-revised of less than 30.18 We used two sided 95%
confidence intervals to summarise non-inferiority testing. As
non-inferiority was confirmed to assist interpretation of results,
we also show the P values generated from tests of superiority
(as recommended previously30).
We undertook ancillary analyses on the primary outcome to
confirm the consistency of any treatment effects across
potentially prognostic subgroups. These subgroups were sex,
age, ethnicity, setting, and baseline depression. These four
subgroup analyses were undertaken using randomised treatment
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as a factor and the baseline level as a covariate (except when
testing the subgroups defined by baseline depression level). The
models also included the subgroup as a factor and the interaction
between randomised treatment and subgroup to test the
significance of any difference in treatment effects across the
subgroups. Given the relatively small sample sizes of some of
the subgroups, the power for testing these interactions is limited
and these results should be considered exploratory only.
The safety data and adverse events were listed by treatment arm
and included details of the event, its severity, and the likely
relatedness to study treatment. A check for safety was carried
out four weeks into the study, in line with usual clinical
practice—that is, to carry out monthly check-ups for young
people with a clinical presentation similar to that of our
participants.
Missing data
For the intention to treat analyses, we estimated missing data
using multiple imputation. This imputation process for each
outcome utilised participant’s sex, age, ethnicity, and setting
and the relevant available assessments of the outcome. Ten
imputations were undertaken for each imputation estimate and
pooled results from these were used.
Results
Participants were recruited at 24 sites, including 15 school based
counselling services, seven youth clinics, and two general
practices fromMay 2009 to July 2010. Follow-upwas completed
by December 2010. Recruitment stopped with 187 participants
(of the anticipated 190) to fit in with school terms and to allow
time to complete follow-up before the extended summer break
(starts in December).
Of 213 young people assessed for eligibility to participate, 26
did not meet the inclusion criteria and 187 were randomised.
Overall, 170 participants (91%) were assessed post-intervention
and 168 (90%) at the three month follow-up. Dropout rates were
low (9%) and comparable between the two groups (SPARX
9/94, treatment as usual 8/93, fig 1⇓). The recruitment and
randomisation strategy led to comparable treatment groups
(table 1⇓).
Treatment as usual
Data on the nature of treatment as usual were available for 83
(89%) participants. Most received counselling (n=74, 89.2%),
some (n=11, 13.3%) were waitlisted for active treatment, and
two (2.4%) were prescribed drugs. The mean number of
treatment as usual sessions was 4.8 (median 4, range 1-20).
Clinicians reported that, for 65 (85.5%) of the young people
receiving counselling, the sessions lasted at least 30 minutes,
and for more than half (n=44, 57.9%) they were for 45 minutes
or longer.
Adherence rates
Eighty out of 94 young people who were allocated to SPARX
returned questionnaires reporting number ofmodules completed.
Adherence rates for SPARX were good, with 69 (86%) of
participants allocated to SPARX completing at least four
modules, 48 (60%) completing all sevenmodules, and 50 (62%)
completing most or all of the homework challenges set. The
most common reasons for non-completion were technical
glitches, lack of time, lack of interest, not finding the resource
helpful, or being physically unwell and unable to attend
appointments.
Outcomes and estimation
Per protocol analysis
A per protocol analysis based on those who completed at least
four of the SPARX modules and did not violate any protocol
specifications was carried out on 143 participants and showed
that SPARX was not inferior to treatment as usual on any
measure. In the SPARX group the mean reduction on our
primary outcome variable (children’s depression rating
scale-revised) was 10.32 (95% confidence interval 8.15 to 12.48)
and in the treatment as usual group 7.59 (5.43 to 9.75), with an
advantage to SPARX of 2.73 (95% confidence interval −0.31
to 5.77; P=0.079). Compared with the treatment as usual groups,
mean changes were significantly higher in the SPARX group
on the Kazdin hopelessness scale for children, the mood and
feelings questionnaire, and the Spence generalised anxiety
subscale (see table 3). The clinical global
impression-improvement response rate did not differ
significantly between the groups (P=0.178).
Intent to treat analysis
Participants in the intention to treat analysis improved
substantially, with amean reduction on the children’s depression
rating scale-revised of 9.05 (95% confidence interval 7.07 to
11.03) for SPARX and 7.45 (5.46 to 9.45) for treatment as usual,
an advantage to SPARX of 1.60 (−1.21 to 4.41; P=0.264)
affirming non-inferiority, as the lower limit on this interval does
not include −5.5 (fig 2⇓). The effect size equates to Cohen’s d
(mean difference divided by the pooled standard deviation of
the change) of 0.3. All secondary outcome measures improved,
with in nearly all instances the SPARX group achieving mean
changes better than those of the treatment as usual group (tables
2⇓ and 3⇓).
Response and remission rates
In the per protocol analysis, remission rates on the primary
outcome were significantly higher in the SPARX group (n=31,
43.7%) than in the treatment as usual group (n=19, 26.4%):
difference 17.3% (95% confidence interval 1.6% to 31.8%;
P=0.030). Rates of response to treatment did not differ
significantly between the groups: 66.2% in the SPARX group
(n=47) and 58.3% in the treatment as usual group (n=42):
difference 7.9% (−7.9% to 24%; P=0.332).
In the intention to treat analysis, at post-intervention 59.6%
(n=56) of those receiving SPARX responded to treatment
compared with 54.8% (n=51) of those receiving treatment as
usual: difference 4.7 (−9.3 to 18.5). Overall, 44.7% (n=42) of
participants in the SPARX group recovered compared with
35.5% (n=33) in the treatment as usual group: difference 9.2
(−4.8 to 22.7). At follow-up, 81.9% (n=77) of those in the
SPARX group and 74.2% (n=69) in the treatment as usual group
had responded (difference 7.7, −4.2 to 19.4) and 58.5% (n=55)
in the SPARX group and 52.7% (n=49) in the treatment as usual
group had recovered (difference 5.8, −8.3 to 19.6). The
differences between groups were not significant.
Planned ancillary analyses
Sex, age, ethnicity, setting, and baseline
depression
As indicated by the interaction terms from the general linear
mixed model analyses, the effectiveness of SPARX was not
related to sex (P=0.962), age (P=0.277), ethnicity (P=0.428),
or setting (school versus non-school, P=0.911). However,
compared with participants who were less depressed at baseline
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those who were more depressed had a significantly (P=0.038)
greater reduction in depression scores in the SPARX group than
in the treatment as usual group (table 4⇓).
Post hoc sensitivity analysis
Unexpectedly, 13.3% of participants in the treatment as usual
group were on a waiting list. The robustness of the findings was
therefore tested by carrying out a post hoc analysis excluding
young people on a waiting list. Non-inferiority of SPARX was
confirmed by this analysis, which actually showed a greater
improvement from SPARX than from treatment as usual on all
measures. The mean changes, respectively, for the SPARX
group and treatment as usual group on the children’s depression
rating scale-revisedwere −8.55 (95% confidence interval −10.44
to −6.66) and −6.41 (−8.44 to −4.38; P=0.130); on the Reynolds
adolescent depression scale-second edition were −9.32 (−11.76
to −6.88) and −6.09 (−8.71 to −3.48; P=0.076); on the moods
and feelings questionnaire were −8.55 (−10.73 to −6.36) and
−5.23 (−7.57 to −2.88; P=0.042); and on the Spence children’s
anxiety scale were −7.88 (−10.04 to −5.72) and −5.32 (−7.63
to −3.01; P=0.11).
Safety and adverse events
Forty nine adverse events were recorded during the study. These
were similarly distributed between the intervention groups.Most
were unrelated to the study (table 5⇓).
Events classified as “possibly” or “probably” related to the study
were rated by severity. One participant in the SPARX group
and two in the treatment as usual group experienced mild
adverse events and eight participants in each group experienced
moderately severe events (for example, worsening of mood,
increase in suicidal thinking). Two participants in the SPARX
group and one in the treatment as usual group experienced
serious events; all these were suicide attempts (one suicide
attempt in the SPARX group occurred between randomisation
and treatment and resulted in withdrawal from the study before
intervention).
Satisfaction with the program
Satisfaction was assessed using a self report questionnaire
designed for the study. The questionnaire consisted of Likert
scales rating the features of the intervention, yes/no answers,
and open ended items. The questionnaire about SPARX differed
slightly from that about treatment as usual because it covered
different aspects of the interventions. Both groups were asked
whether they thought the intervention they had received (SPARX
or treatment as usual) would appeal to other teenagers and
whether they would recommend it to their friends. Eighty
participants in the SPARX group and 71 in the treatment as
usual group completed satisfaction questionnaires immediately
after intervention; 76 (95.0%) of participants in the SPARX
group and 70 (98.6%) in the treatment as usual group (P=0.371)
believed that the type of support they received would appeal to
other teenagers, and 64 (80.5%) of participants in the SPARX
group and 68 (95.8%) in the treatment as usual group (P=0.005)
would recommend the treatment to their friends.
Of those who completed SPARX and returned satisfaction
questionnaires (n=80), 53.2% (n=43) would have liked the
sessions to stay the length they were (most reported taking 20
to 40 minutes to complete each module), 44.3% (n=35) wanted
the sessions to be longer, and 61.5% (n=49) reported that they
completed all or most of the set challenges (“homework”). Box
3 shows themost favourably rated features of both interventions.
Discussion
Acomputerised cognitive behavioural therapy program, SPARX,
was an effective resource for help seeking adolescents with
depression at primary healthcare sites. Use of the program
resulted in a clinically significant reduction in depression,
anxiety, and hopelessness and an improvement in quality of
life. The results are more impressive when it is considered that
SPARXwas entirely a self help resource. The only contact with
a clinician was at recruitment, and the only input from health
professionals during the course of treatment was a brief phone
call after a month. The intervention was at least as good as
treatment as usual in primary healthcare sites in New Zealand
(mainly comprising a high level of face to face counselling by
trained and experienced staff) but would be cheaper and easier
to disseminate. The treatment effects persisted to three months
after the completion of the program. SPARXwasmore effective
than treatment as usual for those who were most depressed at
the start. Adherence rates were high. We did not find any
differential effect across different ethnic groups in New Zealand
or for males and females, although we were underpowered to
detect differences for these subgroups. Most participants found
SPARX useful, believed it would appeal to other teenagers, and
would recommend it to their friends. Some evidence suggested
that participants who completed at least four modules did
significantly better than those who received treatment as usual.
The response and remission rates for participants in the SPARX
group (66% and 44% respectively) compare favourably with
other effective monotherapies, including antidepressants and
cognitive behavioural therapy,31 whereas rates for treatment as
usual were a little lower, possibly because some young people
were on a waiting list. Although the magnitude of change on
the children’s depression rating scale-revised was lower than
that of some of the drug trials, this is to be expected given our
entry criteria. Studies of antidepressants typically include young
people with moderate to severe depressive disorder,32 whereas
we recruited those seeking help for depressive symptoms at a
level that is typical of those who present at primary healthcare
settings.33TheNewZealand guidelines recommend that for mild
to moderate depression, young people should be offered
psychological therapies as preferred treatment, whereas
antidepressants are recommended for those who do not respond
or for those presenting with more severe depression.34 This is
probably the reason for the low rates of drug use in both groups.
Strengths and weaknesses of the study
This study was carried out according to CONSORT guidelines,
in a range of primary healthcare sites. It was adequately powered
to address the primary question of whether SPARXwas inferior
to treatment as usual; the study may, however, have been
underpowered to detect superiority over treatment as usual. The
participants were young people accessing services rather than
those recruited by advertisement, and exclusion criteria were
kept to a minimum to maximise generalisability. The primary
outcome variable was assessed by research assistants blind to
allocation. Care was taken to ensure allocation concealment.
The treatment as usual group received the usual care delivered
in these primary care sites. Our retention rates were excellent.
The study does have some weaknesses. Ideally we would have
liked to have used more than one measure on interview, and
originally we planned to include an interview assessment of
diagnosis, which would also have allowed us to assess for
comorbidity. This proved to be difficult logistically because of
the extra time needed and the difficulties fitting this in with the
services participating in the trial. It would have been easier in
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Most favourably rated features of interventions
SPARX
I could do it at school or in the clinic
I can learn things by myself at my own pace
I could do it at home
It has a New Zealand look and feel
It is made especially for young people
Treatment as usual
Someone is there to support me
Someone who listens to me
I can learn by myself and my own pace
It is different from talking to a friend
It showed me things I didn’t know
a research clinic but this would have compromised the
generalisability to actual clinical service settings. We made the
children’s depression rating scale-revised our primary outcome
variable in line with most studies of antidepressant drugs in this
age group. The design of the study does not allow us to rule out
spontaneous improvement in both groups. However, the mean
duration of an episode of depressive disorder in this age group
is six months35 and, in a comparable population to ours over
50% of young people presenting to primary care settings in the
United Kingdom with similar levels of depression failed to
recover within six months.33 The improvement associated with
SPARX persisted for three months after the intervention was
complete making a placebo effect unlikely. An earlier pilot
study (by a member of our group) of a computerised
intervention, The Journey,15 which informed the development
of SPARX, showed that it was more effective than a placebo
computerised intervention (Cohen’s d=1.7), and a companion
study to this randomised controlled trial16 showed that SPARX
was more effective than a waitlist situation in a group of young
people excluded frommainstream education (Cohen’s d=1.61).
We do not have good data on adherence to treatment as usual.
Clinicians often forgot to fill in our forms, and for some the
number of sessions planned was unclear. Adherence to SPARX
was based on participants’ self report. Ideally, this would have
been more robust, but attempts to collect these data on the
computers at the different sites foundered as we experienced
technical difficulties at some of the sites.
One of the main weaknesses of our study was the heterogeneity
of our treatment as usual group. We considered it unethical to
leave young people who had presented for help untreated. We
did not have the resources to provide an alternative treatment,
such as cognitive behavioural therapy or interpersonal therapy,
the “gold standards.” However, the question for the Ministry
of Health (funder of the study) was whether or not SPARXwas
a reasonable treatment to be offered to those presenting in
primary healthcare settings, including at school based
counselling services, where resources are not sufficient to meet
demand. The sensitivity analysis, in which we removed young
people who were on the waiting list for treatment as usual,
showed that SPARXwas at least as effective as active treatment.
SPARX may also have a place for the 80% of young people
with depressive disorder who never receive treatment,5 some of
whom seem likely to prefer an option to complete therapy in
privacy and in their own time. The number of sites and clinicians
and the work related stress in the various sites made it
impossible to collect robust data on those that refused to take
part in the study. However, clinicians reported that nearly all
the young people they thought were suitable for the study agreed
to take part. A few young people did not want to ask their
parents for consent, and a small number did not want to be in
the study because they did not like computers or because they
specifically wanted to talk to someone. Overall, the rate of
refusal was low and participants in this study are representative
of those presenting for help for depressive symptoms.
Comparison with other studies
This is the third randomised controlled trial of a computerised
intervention for depression in adolescents carried out by our
group. The first, a small pilot study,15 showed a significant
reduction in depressive symptoms compared with a
computerised placebo program, and the second, also a small
study, showed that SPARX was more effective than a waitlist
situation in a group of young people excluded frommainstream
education.16 A recent systematic review13 identified six studies
of four computerised cognitive behavioural therapy interventions
for depression in children and adolescents. Of these, two had
no control group, two were studies of depression prevention in
universal samples of school children, and the last was a
randomised controlled trial comparing brief advice with
motivational interviewing as a strategy to increase adherence
to the computerised intervention. We updated the search with
the same search terms used in the systematic review and
identified two further studies. One, of depression prevention in
a large universal sample of secondary school students,36 showed
a modest effect only among males (Cohen’s d=0.43). The
second was a small pilot study in 15 adolescents, with
encouraging but not definitive results.17 The format of SPARX
led to good engagement with the resource, with 60% of
participants completing all modules compared with 32% in the
YouthMood project,36 although it should be noted that in our
study the results were based on self report, whereas the data
from the YouthMood project were collected automatically by
the computerised program. In the study of Reach Out Central,
the study authors were surprised that participants had accessed
the program so infrequently, with on average boys completing
1.5 sessions and girls 1.6 sessions,37 whereas 86% of our
participants reported that they completed at least four modules.
Participants allocated to SPARX also expressed high levels of
satisfaction. Although 80% of young people in the SPARX
group would recommend the program to their friends,
significantly more young people receiving treatment as usual
(96%)would recommend that intervention to their friends. Some
computerised interventions have been shown to be more
effective than care delivered in general practice,38 but our
participants were largely recruited from school based counselling
services and youth clinics that provided psychological
interventions by, for the most part, trained, experienced
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counsellors, so interventions were well above those usually
available in a general practice setting. SPARX could be made
widely available and could help to address the needs of those
reluctant to seek help from a therapist, those on waiting lists,
and those in areas where access to therapy is poor.
As data on computerised interventions in children and
adolescents with depression were sparse, we have included a
comparison of our findings in relation to the more extensive
data on adults. A recent meta-analysis identified 22 randomised
controlled trials of computerised therapy compared with another
treatment or control condition11 of which six were for depressive
disorder. To be included, the participants had to meet diagnostic
criteria for major depressive disorder, panic disorder, social
phobia, or generalised anxiety disorder. Seventeen of these
studies used a waitlist situation as a comparison. Most11 of the
studies used the internet to deliver cognitive behavioural therapy.
In 12 of the studies, computerised cognitive behavioural therapy
was supported by a therapist to a varying degree. The mean
effect size (Hedges g) for a depressive disorder was 0.78 (based
on six randomised controlled studies). Five randomised
controlled trials compared computerised cognitive behavioural
therapy with face to face treatment for depression or panic
disorder and none showed significant differences between the
treatments. There was no evidence of relapse in the 14 studies
that reported follow-up data (median 26 weeks).
Meaning of the study
SPARX, a computerised self help intervention for adolescents
with symptoms of depression, is at least as good as treatment
as usual in primary healthcare settings in New Zealand and is
a potentially useful treatment. It could be used as the first
component in a stepped care approach to managing depression
in this age group. As the participants in our study were young
people recruited from clinical settings in a large number of sites
and few eligible young people refused to participate, our sample
is likely to be representative of young people seeking and
receiving help for depression. Participants were similar to those
presenting in primary care in a study carried out in the United
Kingdom.33 In our study young people completed the resource
independently, with minimal oversight, mostly on a computer
in the facility where they had sought help, although some
completed it at home. SPARX is an effective resource for
adolescents with depressive symptoms. It is at least as good as
treatment as usual, would be cheaper and easier to disseminate,
and could be used to increase access to therapy. It could provide
access to treatment for young people who may be reluctant to
have more conventional therapy.
Unanswered questions and future directions
Although we had good adherence in the context of a study,
adherence in day to day clinical practice may be different. Use
in other age groups, including children and young adults, could
be investigated. SPARX is likely to be a cheaper way of
delivering treatment than usual treatment, although this needs
to be established by a formal cost-benefit analysis. The
development of an adjunctive clinical monitoring tool to allow
clinicians to track progress of their patients would be
worthwhile.
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Tables
Table 1| Personal characteristics of help seeking adolescents with depression allocated to a computerised cognitive behavioural therapy
intervention (SPARX) or to treatment as usual. Values are percentages (numbers) unless stated otherwise
Treatment as usual group(n=93)SPARX group (n=94)Characteristics
68.8 (64)62.8 (59)Female
31.2 (29)37.2 (35)Male
Age (years):
15.58 (1.66)15.55 (1.54)Mean (SD) age
37.6 (35)41.5 (39)≤14
40.9 (38)40.4 (38)15-16
21.5 (20)18.1 (17)≥17
Ethnicity:
60.2 (56)58.5 (55)New Zealand European
22.6 (21)25.5 (24)Māori
7.5 (7)8.5 (8)Pacific people
8.6 (8)4.3 (4)Asian*
1.1 (1)3.2 (3)Other
Setting:
55.9 (52)54.3 (51)Schools
44.1 (41)45.7 (43)Non-schools
*Chinese, Japanese, Korean, Indian, Malaysian, Fijian Indian, Cambodian, and Thai.
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Table 2| Outcome scores at three study points by intervention group
Mean (SD) treatment as usual groupMean (SD) SPARX* group
Measure 3 month follow-upPost-interventionBaseline3 month follow-upPost-interventionBaseline
Primary outcome
CDRS-R:
30.75 (8.73)36.71 (11.05)43.78 (9.67)29.47 (9.70)34.14 (11.93)44.28 (11.13)PP n=143
29.37 (9.87)35.07 (9.71)42.09 (10.38)28.96 (9.11)33.92 (11.19)43.02 (11.12)ITT n=187
Secondary outcomes
RADS-2:
62.73 (14.84)70.21 (13.43)77.99 (13.46)60.87 (15.01)65.44 (14.89)76.16 (13.35)PP n=143
61.45 (14.68)68.24 (12.31)75.52 (14.42)60.68 (12.51)65.19 (14.52)74.83 (13.35)ITT n=187
MFQ:
19.27 (11.46)24.74 (11.89)32.25 (11.48)15.97 (10.84)19.02 (12.56)28.73 (11.68)PP n=143
17.92 (11.88)22.96 (11.87)29.41 (12.99)15.77 (10.02)19.10 (12.29)27.59 (12.15)ITT n=187
PQ-LES-Q:
33.79 (8.75)29.93 (9.23)26.39 (8.49)34.99 (10.04)33.17 (10.39)27.78 (9.40)PP n=143
34.87 (8.93)31.26 (7.89)28.13 (9.85)35.14 (8.32)33.29 (8.92)28.35 (9.24)ITT n=187
Kazdin HPLS:
3.74 (3.56)5.40 (4.32)6.61 (4.29)3.43 (3.30)4.09 (3.78)6.41 (4.15)PP n=143
3.54 (3.52)4.99 (3.93)6.15 (4.32)3.61 (2.75)4.31 (4.00)6.17 (3.98)ITT n=187
SCAS (total)
27.98 (15.25)32.55 (14.99)38.53 (15.69)25.96 (15.28)29.91 (15.24)39.19 (16.03)PP n=143
26.25 (11.28)29.97 (12.23)35.36 (16.30)25.60 (10.32)28.86 (12.23)37.74 (16.44)ITT n=187
Separation anxiety:
3.18 (2.80)3.90 (3.34)4.54 (3.37)2.31 (2.17)3.07 (2.46)4.07 (2.55)PP n=143
3.00 (2.37)3.66 (2.95)4.15 (3.17)2.25 (2.24)2.91 (2.15)3.79 (2.56)ITT n=187
Social phobia:
7.01 (3.57)7.40 (3.51)8.67 (3.37)6.96 (3.66)7.56 (3.58)9.16 (3.66)PP n=143
6.57 (2.83)6.67 (3.03)8.03 (3.55)6.72 (2.71)7.27 (3.64)8.63 (3.88)ITT n=187
Obsessive-compulsive
disorder:
4.09 (3.86)5.55 (3.82)6.53 (4.01)3.39 (3.21)4.56 (3.42)6.32 (3.63)PP n=143
3.77 (2.71)5.17 (3.21)5.92 (4.17)3.66 (2.63)4.61 (3.24)6.46 (3.71)ITT n=187
Panic/agoraphobia:
4.00 (3.87)4.63 (3.80)6.07 (4.62)3.86 (4.04)4.58 (4.65)6.77 (5.15)PP n=143
3.52 (3.27)4.08 (3.69)5.44 (4.55)3.82 (2.93)4.40 (3.65)6.45 (5.09)ITT n=187
Physical injury fears:
3.78 (2.69)3.82 (3.04)4.32 (3.27)3.85 (2.85)3.98 (2.89)4.61 (2.93)PP n=143
3.62 (1.97)3.61 (1.90)4.10 (3.27)3.76 (1.79)3.73 (1.94)4.43 (3.11)ITT n=187
Generalised anxiety:
5.89 (2.94)7.41 (2.94)8.39 (3.25)5.51 (3.52)6.12 (3.39)8.18 (3.39)PP n=143
5.51 (2.81)6.61 (3.04)7.69 (3.43)5.47 (2.89)6.01 (2.96)7.92 (3.57)ITT n=187
CDRS-R=children’s depression rating scale-revised; PP=per protocol population; ITT=intention to treat population; RADS-2=Reynolds adolescent depression
scale—second edition; MFQ=mood and feelings questionnaire; PQ-LES-Q=pediatric quality of life enjoyment and satisfaction questionnaire; Kazdin HPLS=Kazdin
hopelessness scale for children; SCAS=Spence children’s anxiety scale.
For intention to treat population the means and standard deviations at post-intervention and at three month follow-up include individual imputed estimates.
*Computerised cognitive behavioural therapy intervention.
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Table 3| Mean improvements and mean difference in change scores from baseline to post-intervention and from post-intervention to three
month follow-up
P value
Mean difference in change scores
(95% CI)
Mean change (95% CI) post-intervention
Measure Treatment as usual groupSPARX* group
Baseline to post-intervention
Primary outcome: CDRS-R:
0.0792.73 (−0.31 to 5.77)7.59 (5.43 to 9.75)10.32 (8.15 to 12.48)PP n=143
0.2641.60 (−1.21 to 4.41)7.45 (5.46 to 9.45)9.05 (7.07 to 11.03)ITT n=187
Secondary outcomes:
RADS-2:
0.0603.65 (−0.15 to 7.45)7.55 (4.86 to 10.25)11.20 (8.50 to 13.91)PP n=143
0.1612.62 (−1.04 to 6.27)7.16 (4.54 to 9.79)9.78 (7.12 to 12.43)ITT n=187
MFQ:
0.0323.74 (0.33 to 7.16)6.90 (4.49 to 9.31)10.64 (8.22 to 13.06)PP n=143
0.1182.81 (−0.72 to 6.35)6.08 (3.60 to 8.57)8.90 (6.56 to 11.24)ITT n=187
PQ-LES-Q:
0.0772.23 (−0.24 to 4.71)3.47 (1.72 to 5.23)5.71 (3.95 to 7.47)PP n=143
0.1241.87 (−0.51 to 4.26)3.14 (1.43 to 4.85)5.01 (3.40 to 6.63)ITT n=187
Kazdin HPLS:
0.0351.22 (0.09 to 2.35)1.16 (0.36 to 1.96)2.37 (1.57 to 3.18)PP n=143
0.2180.69 (−0.41 to 1.79)1.15 (0.41 to 1.89)1.84 (1.07 to 2.62)ITT n=187
SCAS (total):
0.0753.09 (−0.31 to 6.50)6.09 (3.67 to 8.50)9.18 (6.76 to 11.60)PP n=143
0.0992.80 (−0.53 to 6.13)5.69 (3.28 to 8.11)8.50 (6.05 to 10.94)ITT n=187
Separation anxiety:
0.1530.52 (−0.19 to 1.23)0.58 (0.08 to 1.09)1.10 (0.60 to 1.61)PP n=143
0.1700.51 (−0.22 to 1.23)0.43 (−0.12 to 0.99)0.94 (0.44 to 1.44)ITT n=187
Social phobia:
0.7730.14 (−0.78 to 1.05)1.37 (0.72 to 2.02)1.51 (0.85 to 2.16)PP n=143
0.566−0.26 (−1.14 to 0.62)1.51 (0.87 to 2.15)1.25 (0.64 to 1.87)ITT n=187
Obsessive-compulsive disorder:
0.0650.88 (−0.05 to 1.81)0.91 (0.25 to 1.57)1.79 (1.12 to 2.45)PP n=143
0.0300.89 (0.09 to 1.70)0.82 (0.25 to 1.40)1.72 (1.14 to 2.30)ITT n=187
Panic/agoraphobia:
0.3520.47 (−0.52 to 1.47)1.59 (0.89 to 2.30)2.06 (1.36 to 2.77)PP n=143
0.5530.29 (−0.67 to 1.24)1.56 (0.88 to 2.23)1.84 (1.19 to 2.50)ITT n=187
Physical injury fears:
0.4750.06 (−0.49 to 0.61)0.55 (0.16 to 0.94)0.61 (0.22 to 1.00)PP n=143
0.6320.13 (−0.39 to 0.65)0.53 (0.15 to 0.90)0.65 (0.29 to 1.02)ITT n=187
Generalised anxiety:
0.0370.91 (0.06 to 1.75)1.18 (0.58 to 1.79)2.09 (1.48 to 2.69)PP n=143
0.0690.73 (−0.06 to 1.52)1.11 (0.55 to 1.67)1.84 (1.27 to 2.41)ITT n=187
Post-intervention to three month follow-up
Primary outcome: CDRS-R:
0.412−1.28 (−4.35 to 1.79)5.95 (3.79 to 8.12)4.68 (2.50 to 6.86)PP n=143
0.609−0.75 (−3.61 to 2.12)5.70 (3.65 to 7.76)4.96 (2.87 to 7.05)ITT n=187
Secondary outcomes
RADS-2:
0.178−2.91 (−7.17 to 1.34)7.48 (4.48 to 10.48)4.57 (1.58 to 7.59)PP n=143
0.280−2.28 (−6.41 to 1.86)6.79 (3.91 to 9.66)4.51 (1.55 to 7.47)ITT n=187
MFQ:
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Table 3 (continued)
P value
Mean difference in change scores
(95% CI)
Mean change (95% CI) post-intervention
Measure Treatment as usual groupSPARX* group
0.179−2.42 (−5.97 to 1.12)5.47 (2.96 to 7.96)3.04 (0.53 to 5.56)PP n=143
0.314−1.71 (−5.05 to 1.62)5.04 (2.74 to 7.35)3.33 (0.99 to 5.67)ITT n=187
PQ-LES-Q:
0.152−2.03 (−4.82 to 0.76)3.85 (1.88 to 5.81)1.82 (0.16 to 3.80)PP n=143
0.179−1.77 (−0.81 to 4.34)3.62 (1.80 to 5.43)1.85 (0.02 to 3.68)ITT n=187
Kazdin HPLS:
0.063−1.01 (−2.08 to 0.06)1.67 (0.92 to 2.42)0.66 (0.10 to 1.41)PP n=143
0.112−0.75 (−1.68 to 0.18)1.46 (0.76 to 2.15)0.70 (0.03 to 1.38)ITT n=187
SCAS (total):
0.726−0.62 (−4.10 to 2.86)4.57 (2.12 to 7.02)3.95 (1.48 to 6.42)PP n=143
0.778−0.46 (−3.68 to 2.76)3.72 (1.40 to 6.05)3.26 (1.01 to 5.51)ITT n=187
Separation anxiety:
0.9140.04 (−0.71 to 0.80)0.72 (0.19 to 1.25)0.76 (0.23 to 1.30)PP n=143
0.9980 (−0.68 to 0.69)0.66 (0.15 to 1.17)0.66 (0.19 to 1.13)ITT n=187
Social phobia:
0.6400.21 (−0.67 to 1.09)0.40 (0.22 to 1.02)0.61 (0.02 to 1.23)PP n=143
0.2990.44 (−0.40 to 1.28)0.10 (−0.48 to 0.68)0.55 (−0.05 to 1.15)ITT n=187
Obsessive-compulsive disorder:
0.516−0.29 (−1.18 to 0.60)1.46 (0.84 to 2.09)1.17 (0.54 to 1.80)PP n=143
0.268−0.45 (−1.25 to 0.35)1.40 (0.83 to 1.97)0.95 (0.39 to 1.51)ITT n=187
Panic/agoraphobia:
0.8670.09 (−0.95 to 1.13)0.63 (0.10 to 1.36)0.72 (0.02 to 1.46)PP n=143
0.9750.02 (−0.94 to 0.97)0.57 (−0.09 to 1.22)0.58 (−0.09 to 1.25)ITT n=187
Physical injury fears:
0.7810.09 (−0.54 to 0.72)0.04 (−0.40 to 0.48)0.13 (−0.32 to 0.58)PP n=143
0.9340.02 (−0.59 to 0.55)0.01 (−0.41 to 0.40)0.03 (−0.44 to 0.37)ITT n=187
Generalised anxiety:
0.170−0.64 (−1.56 to 0.28)1.26 (0.61 to 1.90)0.61 (0.04 to 1.27)PP n=143
0.209−0.56 (−1.42 to 0.31)1.10 (0.49 to 1.70)0.54 (−0.08 to 1.16)ITT n=187
PP=per protocol population; ITT=intention to treat population.
Means and confidence intervals are derived from the linear mixed modelling analysis. Positive values favour SPARX (negative values favour treatment as
usual).
*Computerised cognitive behavioural therapy intervention.
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Table 4| Depression severity at entry and mean changes on children’s depression rating scale-revised by intervention
Mean change (95% CI)
Severity of depression* Treatment as usual groupSPARX† group
2.94 (0.45 to 5.43)5.61 (3.06 to 8.16)Possible (n=103)
12.90 (9.49 to 16.32)10.60 (7.46 to 13.74)Likely (n=62)
12.86 (7.32 to 18.40)21.73 (16.19 to 27.27)Very likely (n=22)
*Children’s depression rating scale-revised raw scores: 30-42 (it is possible that a depressive disorder might be confirmed in a comprehensive diagnostic evaluation),
43-57 inclusive (a depressive disorder is likely to be confirmed in a comprehensive diagnostic evaluation), and 58-72 inclusive (a depressive disorder is very likely
to be confirmed).7
†Computerised cognitive behavioural therapy intervention.
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Table 5| Adverse events recorded during study
Treatment as usual groupSPARX* groupVariables
2128No of adverse events
Relation to study participation:
1017Unrelated
1011Possible
10Probable
Outcome:
2026Continue with study
12Withdrawn from study
*Computerised cognitive behavioural therapy intervention.
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Figures
Fig 1 Flow of participants through study
Fig 2 Changes (standard errors) on children’s depression rating scale-revised (CDRS-R)
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